TK inhibitors
Roche EGFR Mutation Test Approved by FDA as Companion Diagnostic for NSCLC
Roche's real-time PCR test detects defined mutations of the epidermal growth factor receptor gene in DNA from non-small cell lung cancer patients.
Cervical Cancer Exomes Point to Potentially Targetable HER, PIK3CA Pathway Changes
Exome sequences from dozens of cervical cancer tumor or primary cell line samples revealed recurrent alterations affecting ERBB2/HER2 and PIK3CA pathways.
Angsana Cancer Fusion Panel Selected for Ignyta Clinical Trial
Angsana will support a Phase 2 basket trial for a tyrosine kinase inhibitor that targets tumors harboring TRK, ROS1, and ALK fusions.
PGDx, Blueprint Team to Identify Genomic Alterations in Cancer for Targeted Drug Development
Premium
Originally published May 28.
AstraZeneca Paying for Genetic Testing Services for UK Lung Cancer Patients Receiving Iressa
Premium
Ahead of a cost-effectiveness appraisal by UK's NICE, AstraZeneca is paying for EGFR mutation testing for non-small cell lung cancer patients to determine if they will benefit from treatment with Iressa. The genetic testing program is part of a patient access scheme the company has agreed to with the National Health Service to provide more granularity about the cost and value of the treatment.